These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 30257336)

  • 1. Multi-drug resistant Mycobacterium tuberculosis & oxidative stress complexity: Emerging need for novel drug delivery approaches.
    Dua K; Rapalli VK; Shukla SD; Singhvi G; Shastri MD; Chellappan DK; Satija S; Mehta M; Gulati M; Pinto TJA; Gupta G; Hansbro PM
    Biomed Pharmacother; 2018 Nov; 107():1218-1229. PubMed ID: 30257336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent therapeutic approaches for the management of tuberculosis: Challenges and opportunities.
    Patil K; Bagade S; Bonde S; Sharma S; Saraogi G
    Biomed Pharmacother; 2018 Mar; 99():735-745. PubMed ID: 29710471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in nanotechnology-based carrier systems for targeted delivery of bioactive drug molecules with special emphasis on immunotherapy in drug resistant tuberculosis - a critical review.
    Singh J; Garg T; Rath G; Goyal AK
    Drug Deliv; 2016 Jun; 23(5):1676-98. PubMed ID: 26289212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Nanotechnological Approaches for an Effective Delivery of Bioactive Drug Molecules to Overcome Drug Resistance Tuberculosis.
    Garg T; Rath G; Murthy RR; Gupta UD; Vatsala PG; Goyal AK
    Curr Pharm Des; 2015; 21(22):3076-89. PubMed ID: 26027577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Management of Drug-resistant Mycobacterium tuberculosis Strains: Pathogen-targeted Versus Host-directed Treatment Approaches.
    Al-Ghafli H; Al-Hajoj S
    Curr Pharm Biotechnol; 2019; 20(4):272-284. PubMed ID: 30062961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Attributable factors to the emergence of multidrug-resistant Mycobacterium tuberculosis based on the observation of consecutive drug resistance test results].
    Fujino T; Hasegawa N; Satou R; Komatsu H; Kawada K
    Kekkaku; 1998 Jul; 73(7):471-6. PubMed ID: 9739579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Approaches to combined therapy of pulmonary tuberculosis in adolescents excreting drug-resistant Mycobacterium tuberculosis].
    Firsova VA; Rusakova LI; Grigor'eva ZP; Ryzhova AP; Iatskova TV; Poluéktova FG
    Probl Tuberk; 2001; (1):28-30. PubMed ID: 11337776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New treatment options for multidrug-resistant tuberculosis.
    Field SK; Fisher D; Jarand JM; Cowie RL
    Ther Adv Respir Dis; 2012 Oct; 6(5):255-68. PubMed ID: 22763676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanoparticle delivery of anti-tuberculosis chemotherapy as a potential mediator against drug-resistant tuberculosis.
    Smith JP
    Yale J Biol Med; 2011 Dec; 84(4):361-9. PubMed ID: 22180674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced cellular systems to study tuberculosis treatment.
    Bielecka MK; Elkington P
    Curr Opin Pharmacol; 2018 Oct; 42():16-21. PubMed ID: 29990957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptide deformylase--a promising therapeutic target for tuberculosis and antibacterial drug discovery.
    Sharma A; Khuller GK; Sharma S
    Expert Opin Ther Targets; 2009 Jul; 13(7):753-65. PubMed ID: 19530983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is Shorter Treatment Regimen for Multidrug-resistant Tuberculosis feasible in Indian Children?
    Shah I
    Indian Pediatr; 2017 Feb; 54(2):160. PubMed ID: 28285296
    [No Abstract]   [Full Text] [Related]  

  • 14. Facing multi-drug resistant tuberculosis.
    Sotgiu G; Migliori GB
    Pulm Pharmacol Ther; 2015 Jun; 32():144-8. PubMed ID: 24792579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanocarrier-based interventions for the management of MDR/XDR-TB.
    Mustafa S; Pai RS; Singh G; Kusum Devi V
    J Drug Target; 2015 May; 23(4):287-304. PubMed ID: 25766078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug susceptibility profiles of pulmonary Mycobacterium tuberculosis isolates from patients in informal urban settlements in Nairobi, Kenya.
    Kerubo G; Amukoye E; Niemann S; Kariuki S
    BMC Infect Dis; 2016 Oct; 16(1):583. PubMed ID: 27756241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of resistance in multi drug resistant tuberculosis patients.
    Irfan S; Hassan Q; Hasan R
    J Pak Med Assoc; 2006 Sep; 56(9):397-400. PubMed ID: 17091751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates from Pakistan 2010-2014: Implications for disease control.
    Jabeen K; Shakoor S; Malik F; Hasan R
    Int J Mycobacteriol; 2015 Mar; 4 Suppl 1():47-8. PubMed ID: 27128617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Consideration on the use of injectable anti-tuberculosis drufgs in the treatment of drug-resistant tuberculosis in china].
    Liu YH
    Zhonghua Jie He He Hu Xi Za Zhi; 2019 Jun; 42(6):401-404. PubMed ID: 31189224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current therapeutic delivery approaches using nanocarriers for the treatment of tuberculosis disease.
    Biswas B; Misra TK; Ray D; Majumder T; Bandyopadhyay TK; Bhowmick TK
    Int J Pharm; 2023 Jun; 640():123018. PubMed ID: 37149113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.